c-erbB-2和EGFR在外阴白色病变中的表达

目的检测外阴白色病变组织中c-erbB-2和EGFR的表达,探讨其在该病发病机制中的作用及相互关系。方法采用免疫组织化学方法检测39例患者的外阴白色病变其中硬化性苔癣(LS)11例,鳞状上皮细胞增生(SH)19例,SH合并LS9例,并以此分组。组织中c-erbB-2、EGFR的表达情况。以11例正常外阴皮肤石蜡包埋组织作为对照组。结果EGFR基因蛋白在对照组与SH组、LS合并SH组间的表达差异有统计学意义(χ2=8.56,P<0.05),SH组与其他各组间差异有统计学意义(χ2=7.79,P<0.01),LS组与对照组及LS合并SH组间差异无统计学意义(χ2=1.23,P>0.05)。在对照组与LSH组和LS合并SH组间c-erbB-2基因蛋白表达差异有统计学意义(χ2=11.40,P<0.01)。EGFR基因蛋白阳性表达产物位于表皮基底层和棘层,主要位于细胞膜,部分位于细胞质内,而c-erbB-2基因蛋白阳性表达产物位于表皮基底层?颗粒层和棘层上部,主要位于细胞膜,部分位于细胞质内。在外阴白色病变患者中,c-erbB-2与EGFR的表达有相关性(r=0.388,P=0.015)。结论c-erbB-2、EGFR的过度表达可能与外阴鳞状上皮细胞增生的发生有关,也可能是外阴鳞状上皮细胞增生较硬化性苔藓易于癌变的原因之一。c-erbB-2、EGFR基因表达有相关性。c-erbB-2、EGFR在SH组中的过度表达使基于二者的免疫靶向治疗成为可能。

Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR:what's new and what's enough

Historically,non-small cell lung cancer(NSCLC) is divided into squamous and nonsquamous subtypes based on histologic features.With a growing number of oncogenic drivers being identified in squamous and nonsquamous NSCLC,this malignancy has been recently divided into several distinct subtypes according to the specific molecular alterations.This new paradigm has substantially highlighted the treatment of advanced NSCLC,shifting it from standard chemotherapy according to specific histologic subtypes to targeted therapy according to specific oncogenic drivers.The application of epidermal growth factor receptor(EGFR)-tyrosine kinase inhibitors(TKIs) in NSCLC patients harboring activating EGFR mutations has been a representative model of precise medicine in the treatment of NSCLC.As the role of EGFR-TKIs in routine management of patients with advanced NSCLC has been well established,this review provides an overview of alternative targeted therapy in the treatment of NSCLC,including EGFR-TKIs for patients with wild-type EGFR NSCLC,as well as other targeted agents either clinical available or in early- to late-stage development.